Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1526 ARTÍCULOS , VIENDO DEL 1141 AL 1155

Early Detection of Mild Cognitive Impairment (MCI) in Primary Care

Sabbagh MN, Boada M, Borson S, Chilukuri M, Dubois B, Ingram J, Iwata A, Porsteinsson AP, Possin KL, Rabinovici GD, Vellas B, Chao S, Vergallo A, Hampel H.

J Prev Alzheimers Dis. 2020;7(3):165-170. doi: 10.14283/jpad.2020.21.

Buccal Mucosa Biomarkers in Alzheimer's Disease

Avramouli A, Vlamos P.

Adv Exp Med Biol. 2020;1195:49-56. doi: 10.1007/978-3-030-32633-3_8.

Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease

Khan S, Barve KH, Kumar MS.

Curr Neuropharmacol. 2020;18(11):1106-1125. doi: 10.2174/1570159X18666200528142429.

Exploring the Potential of Neuroproteomics in Alzheimer's Disease

Uddin MS, Kabir MT, Jakaria M, Sobarzo-Sánchez E, Barreto GE, Perveen A, Hafeez A, Bin-Jumah MN, Abdel-Daim MM, Ashraf GM.

Curr Top Med Chem. 2020;20(25):2263-2278. doi: 10.2174/1568026620666200603112030.

Biosensing: The best alternative for conventional methods in detection of Alzheimer's disease biomarkers

Mobed A, Hasanzadeh M.

Int J Biol Macromol. 2020 Oct 15;161:59-71. doi: 10.1016/j.ijbiomac.2020.05.257. Epub 2020 Jun 3.

Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials

Rafii MS.

CNS Drugs. 2020 Aug;34(8):785-794. doi: 10.1007/s40263-020-00740-6.

Advent of Proteomic Tools for Diagnostic Biomarker Analysis in Alzheimer's Disease

Singh M, Singh SP, Dubey PK, Rachana R, Mani S, Yadav D, Agarwal M, Agarwal S, Agarwal V, Kaur H.

Curr Protein Pept Sci. 2020;21(10):965-977. doi: 10.2174/1389203721666200615173213.

Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions

Bermejo-Pareja F, Del Ser T, Valentí M, de la Fuente M, Bartolome F, Carro E.

Alzheimers Dement. 2020 Aug;16(8):1196-1204. doi: 10.1002/alz.12107. Epub 2020 Jun 16.

The flash visual evoked potential-P2 and the detection of amnestic mild cognitive impairment: A review of empirical literature

Arruda JE, McInnis MC, Steele J.

Int J Psychophysiol. 2020 Sep;155:162-167. doi: 10.1016/j.ijpsycho.2020.05.012. Epub 2020 Jun 18.

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks

Guthrie H, Honig LS, Lin H, Sink KM, Blondeau K, Quartino A, Dolton M, Carrasco-Triguero M, Lian Q, Bittner T, Clayton D, Smith J, Ostrowitzki S.

J Alzheimers Dis. 2020;76(3):967-979. doi: 10.3233/JAD-200134.

Towards a Redefinition of Cognitive Frailty

Mantovani E, Zucchella C, Schena F, Romanelli MG, Venturelli M, Tamburin S.

J Alzheimers Dis. 2020;76(3):831-843. doi: 10.3233/JAD-200137.

Design and Rationale of the PACt-MD Randomized Clinical Trial: Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression

Rajji TK, Bowie CR, Herrmann N, Pollock BG, Bikson M, Blumberger DM, Butters MA, Daskalakis ZJ, Fischer CE, Flint AJ, Golas AC, Graff-Guerrero A, Kumar S, Lourenco L, Mah L, Ovaysikia S, Thorpe KE, Voineskos AN, Mulsant BH; PACt-MD Study Group.

J Alzheimers Dis. 2020;76(2):733-751. doi: 10.3233/JAD-200141.

Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model

Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, Ward M, Siddiqui O, Paul R, Gilfillan S, Ibrahim A, Rhinn H, Tassi I, Rosenthal A, Schwabe T, Colonna M.

J Exp Med. 2020 Sep 7;217(9):e20200785. doi: 10.1084/jem.20200785.

Biosensors for detection of Tau protein as an Alzheimer's disease marker

Ameri M, Shabaninejad Z, Movahedpour A, Sahebkar A, Mohammadi S, Hosseindoost S, Ebrahimi MS, Savardashtaki A, Karimipour M, Mirzaei H.

Int J Biol Macromol. 2020 Nov 1;162:1100-1108. doi: 10.1016/j.ijbiomac.2020.06.239. Epub 2020 Jun 27.

Leveraging preclinical models for the development of Alzheimer disease therapeutics

Scearce-Levie K, Sanchez PE, Lewcock JW.

Nat Rev Drug Discov. 2020 Jul;19(7):447-462. doi: 10.1038/s41573-020-0065-9. Epub 2020 Apr 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias